Oncimmune Holdings PLC Oncimmune to Present at 2019 CBIIC
September 18 2019 - 1:01AM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
18 September 2019
18 September 2019
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune to Present at 2019 China BioMed Innovation and
Investment Conference in Suzhou, China
Oncimmune Holdings plc (AIM: ONC.L), a Leading Global
Immunodiagnostics Group, will be keynoting the China BioMed
Innovation and Investment Conference (CBIIC) on Sunday 22(nd)
September 2019, at 9:00 am CST (2:00 am BST) in Suzhou, China.
The Company's presentation will be made available under the IR
section on Oncimmune's website on Monday 23(rd) September 2019.
Adam Hill, Chief Executive Officer of Oncimmune, will be
presenting an overview of Oncimmune, including progress in
delivering the forward strategy. He will be available to take
questions following the event.
-Ends-
For further information:
Oncimmune Holdings plc
Cléa Rosenfeld, Head of Investor Relations
ir@oncimmune.com
Media enquiries:
FTI Consulting
Brett Pollard, Andrew Ward
oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About CBIIC
CBIIC was established in 2016 and initiated by China
Pharmaceutical Innovation and Research Development Association
(PhIRDA). CBIIC aims to promotes the communication between the
pharmaceutical industry and the investment community in order to
facilitate innovation in unmet clinical needs. To that end, CBIIC
holds an annual investor conference and this year around 3500
participants are expected to attend.
About Oncimmune
Beating cancer, one test at a time
The battle against cancer hinges on early detection and then the
delivery of effective treatment. Oncimmune is working to
revolutionise both the detection of cancer and its treatment by
harnessing the sophisticated disease detecting capabilities of the
immune system to find cancer in its early stages. Our range of
diagnostic tests assist clinicians to identify the presence of
cancer four years or more before standard clinical diagnosis,
whilst our technology platform and sample biobanks are helping
healthcare companies to develop new cancer treatments.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT(R) Lung and EarlyCDT Liver. To date, over 155,000 tests
have been performed for patients worldwide. EarlyCDT Lung was also
used in what is believed to be the largest randomised controlled
study for the early detection of lung cancer using biomarkers, the
successful National Health Service (NHS) ECLS study of 12,209
high-risk smokers in Scotland which demonstrated EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a CLIA lab in Kansas, US as well as an office in
London, UK and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFSEAEIDLIA
(END) Dow Jones Newswires
September 18, 2019 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024